AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04076800 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
Study NCT03672006 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alteplase (recombinant t-PA)
Description: Medication administered to dwell in central venous catheter
Study NCT03672006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Medication administered to dwell in central venous catheter
Study NCT02789566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Primaquine 30 mg taken after meal in the morning.
Study NCT01978717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epidural anesthesia
Study NCT01978717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: Patients received general anesthesia for surgery
Study NCT00275834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: zonisamide 400 mg, 200 mg, or placebo
Study NCT00275834 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zonisamide
Description: zonisamide 400 mg, 200 mg, or placebo
Study NCT02646501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Antiarrhythmic drug
Study NCT01200628 — intervention group
Intervention type: BEHAVIORAL
Intervention: DEPITAC
Description: heteroevaluation scale by a nurse during hospitalization
Study NCT02646501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug
Description: Antiarrhythmic drug
Study NCT02646501 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous stellate ganglion block (PSGB)
Description: percutaneous stellate ganglion block (PSGB)
Study NCT03774030 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: several virtual 3-D complex audio environments
Description: The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
Study NCT01445197 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biostate
Description: 200 IU/kg administered daily
Study NCT03878901 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: high risk warm
Description: Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming
Study NCT03878901 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: moderate risk warm
Description: 30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation
Study NCT03878901 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: low risk warm
Description: 30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
Study NCT02711878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Move Program
Description: Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
Study NCT02711878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Let's Flex Program
Description: Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
Study NCT02711878 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Motivational Interviewing
Description: Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
Study NCT02711878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing
Description: Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
Study NCT02538822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dynamic imaging
Description: In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
Study NCT02538822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical testing
Description: In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
Study NCT03855267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol 20 MG/ML
Description: Pump propofol to keep bispectral index within 40 # 60
Study NCT03855267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 20 mg/ml , etomidate 2 mg/ml
Description: Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
Study NCT03878901 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: passive warming
Description: cotton blanket warming through operation
Study NCT01996124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol Fumarate
Description: 150 mcg inhalation powder, hard capsules, once daily
Study NCT01996124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fructose, dry inhalation powder, hard capsules via breezhaler
Study NCT03102060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo gluten free diet
Study NCT03102060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03076723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in shunt opening pressure
Description: An individually determined change in shunt opening pressure is compared to no change in opening pressure.
Study NCT03076723 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Simulated change in shunt opening pressure
Description: The shunt opening pressure is reset to the same setting.
Study NCT04291768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened antibiotic treatment
Description: Shortened antibiotic treatment of 5 days. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
Study NCT04291768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard antibiotic treatment
Description: Standard antibiotic treatment of minimum 7 days at the discretion of treating physician. Participation in the study will only affect treatment duration and will have no influence on the choice of treatment in respect to type and dose of antibiotic treatment.
Study NCT05082311 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study
Study NCT00853138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavioral therapy
Description: In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week.
Study NCT03875664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Extended-release local anesthetic
Study NCT03875664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - injection
Description: Injectable normal saline solution
Study NCT01688115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video
Description: The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
Study NCT01688115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
Study NCT02369419 — intervention group
Intervention type: OTHER
Intervention: Frailty
Description: CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as \<14/17 points using the ONCODAGE score
Study NCT04751188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 MG Oral Tablet
Description: Bezafibrate one tablet every 12 hours for six months.
Study NCT04751188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet every 12 hours for six months.
Study NCT04751188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: At a dose of 13 to 15 mg per Kg per day.
Study NCT04751188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic Acid
Description: At a dose of 13 to 15 mg per Kg per day.
Study NCT00757822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
Study NCT00757822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
Study NCT03473795 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire forms
Description: The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
Study NCT03473795 — intervention group
Intervention type: OTHER
Intervention: Bio-specimen samples
Description: Samples can include tissue, blood, urine, saliva, hair and nail clipping.
Study NCT05401188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day-surgery unit where they were discharged according to ALDRETE criteria.
Study NCT05401188 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hospitalization
Description: Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward.
Study NCT02885376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dentoxol
Description: Mouthrinse
Study NCT02885376 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouthrinse
Study NCT04430153 — intervention group
Intervention type: OTHER
Intervention: Class 1 Medical Device CE certified devices: ActiGraph wGT3X-BT accelerometer
Description: Accelerometers on both patients' wrists will give insight into the daily life upper limb use.
Study NCT03514290 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-lever laser
Description: Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
Study NCT03514290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth bleaching
Description: Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
Study NCT03514290 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tooth bleaching
Description: Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
Study NCT03514290 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The laser tip was positioned similarly to experimental group but without light irradiation
Study NCT04028557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Support Systems, Clinical
Description: Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
Study NCT04028557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Support Systems, Clinical
Description: Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 1 or 2 doses
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™ HB+Hib
Description: Intramuscular, 3 doses
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix™ HB+Hib
Description: Intramuscular, 3 doses
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar™
Description: Intramuscular, 3 doses
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar™
Description: Intramuscular, 3 doses
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin™
Description: Oral, 3 doses
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin™
Description: Oral, 3 doses
Study NCT01098474 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate™
Description: Intramuscular, 3 doses
Study NCT01408602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRC375
Description: MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
Study NCT01408602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
Study NCT01408602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRC375 150mg
Description: MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
Study NCT03669835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mare milk supplement
Description: Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
Study NCT03669835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
Study NCT03669835 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard therapy
Description: For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
Study NCT02855749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided percutaneous tracheostomy
Description: to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
Study NCT00830492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene citrate
Description: 100 mg from cycle day 3 through 7
Study NCT00830492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: cycle day 8
Study NCT02699203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Description: Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
Study NCT02619994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Study NCT02619994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid
Study NCT02619994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study NCT02619994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Study NCT02619994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locally-used WHO-approved MDR-TB regimen in Korea
Study NCT02898662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1419
Description: Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
Study NCT02898662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
Study NCT03104270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
Study NCT03104270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide PO at 3mg
Study NCT03104270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
Study NCT03104270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
Study NCT00830492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: cycle day 8
Study NCT00830492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
Study NCT00830492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotopin (HMG)
Description: 75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
Study NCT00830492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buserelin
Description: Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (\<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
Study NCT00830492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rFSH
Description: 150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.